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Abstract
Objective The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple scle-
rosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has 
been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations.
Methods Patients with RMS were randomized to either ocrelizumab 600 mg administered by intravenous infusion every 
24 weeks or subcutaneous IFN β-1a 44 µg three times per week throughout the 96-week treatment period. Relapse, disability, 
and MRI outcomes were analyzed for predefined and post hoc subgroups based on demographic and disease characteristics 
along with prior treatment using appropriate statistical tests to determine the treatment effect in subgroups and treatment-
by-subgroup interactions.
Results The significant treatment benefit of ocrelizumab, versus IFN β-1a, observed in the overall OPERA I and OPERA II 
pooled populations was maintained across most subgroup strata for all endpoints, including annualized relapse rate, disability 
progression, and MRI outputs.
Conclusions The treatment effect of ocrelizumab versus IFN β-1a, measured by clinical and MRI outcomes, was maintained 
across most of the subgroups and strata of interest, and the pattern of treatment benefit across all subgroups was consistent 
with that from the pooled OPERA studies.
Keywords Relapsing · Multiple sclerosis · Ocrelizumab · Subgroup · Interferon β-1a · Phase 3
Introduction
The efficacy and safety of ocrelizumab, a humanized  CD20+ 
B-cell selective monoclonal antibody, versus high-dose, high-
frequency interferon (IFN) β-1a in patients with relapsing 
multiple sclerosis (RMS), was demonstrated in the phase III 
OPERA I and OPERA II studies [1]. The identical study 
designs, comparable baseline demographics and disease 
characteristics of patients, and the evidence of no interaction 
between treatment and trial on the primary endpoint (annual-
ized relapse rate [ARR]) between the OPERA I and OPERA 
II trials [1], permitted pooling of trial data.
Compared with IFN β-1a, treatment with ocrelizumab 
resulted in a 47% lower ARR (primary endpoint; p < 0.001) 
in the analysis of the pooled OPERA I and OPERA II 
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intent-to-treat (ITT) population [2]. Similarly, treatment 
with ocrelizumab was associated with relatively lower rates 
of disability progression confirmed at 12 weeks (12W-CDP; 
40%) and at 24 weeks (24W-CDP; 40%) in the prespeci-
fied pooled analysis of both studies. These data were further 
supported by a significantly greater suppression of develop-
ment of new areas of inflammation (assessed by MRI of the 
brain with the use of gadolinium enhancement) and new or 
newly enlarged plaque formation (as measured by lesions on 
T2-weighted MRI) [1].
The current analyses were undertaken to understand if 
the treatment effects of ocrelizumab are consistent across 
subgroups of patients with different baseline characteris-
tics; to describe the efficacy of ocrelizumab in patient sub-
groups relating to disability and clinical and MRI disease 
activity; and to describe the efficacy of ocrelizumab in both 
treatment-naïve patients and those previously treated with 
disease-modifying therapy (DMT).
Methods
Trial design and patients
The methodology of the identically designed phase III 
OPERA I (NCT01247324) and OPERA II (NCT01412333) 
studies has been reported previously [1]. Patients (aged 
18–55 years, McDonald criteria [2010] diagnosis of MS 
[3], baseline Expanded Disability Status Scale [EDSS] score 
0–5.5, ≥ 2 documented clinical relapses within the previous 
2 years or one clinical relapse within the year before screen-
ing) were randomized (1:1) to treatment with either ocreli-
zumab 600 mg administered by intravenous infusion every 
24 weeks, or subcutaneous IFN β-1a 44 µg three times per 
week throughout the 96-week treatment period. All patients 
provided written informed consent.
Statistical analyses
Statistical approaches, including sample size calculations 
and analyses of primary and secondary endpoints, have been 
described previously [1].
Subgroup analyses, based on data from the 96-week 
double-blind treatment period, of the primary (ARR) and 
secondary endpoints were assessed in the ITT population 
(all randomized patients [ocrelizumab, n = 827; IFN β-1a, 
n = 829]); analyses of no evidence of disease activity (NEDA) 
were conducted in the modified ITT (mITT) population 
(ocrelizumab, n = 761; IFN β-1a, n = 759), where patients 
withdrawn from the trial for reasons other than efficacy fail-
ure or death and who had no evidence of clinical disease 
activity at the time of treatment discontinuation in the trial 
were excluded [1].
Prespecified subgroups were: study (OPERA I versus 
OPERA II), age (< 40 versus ≥ 40 years), sex, BMI (< 25 kg/m2 
versus ≥ 25 kg/m2), region (USA versus rest of world), baseline 
EDSS score (< 4 versus ≥ 4), baseline gadolinium-enhancing 
T1 lesion status (0 versus ≥ 1), and pre-treated patients with 
active disease (pre-treated for ≥ 1 year with either ≥ 1 relapse 
in the year prior to randomization or ≥ 1 baseline T1 gadolin-
ium-enhancing lesion) or highly active disease (≥ 1 relapse in 
the year prior to randomization and ≥ 9 T2 lesions or ≥ 1 T1 
gadolinium-enhancing lesion at baseline). Additional post hoc 
subgroups, included because of their clinical relevance, con-
sisted of: baseline EDSS score (< 2.5 versus ≥ 2.5 [for further 
evaluation of patients with lower disability at baseline]), prior 
DMT use within the 2 years prior to study inclusion (yes versus 
no), prior relapse (≤ 1 versus ≥ 2), and baseline normalized 
brain volume (≥ 1500 cm3 versus < 1500 cm3).
Statistical analyses of endpoint by subgroup
Subgroup-level treatment comparisons were used to deter-
mine whether the treatment effects of ocrelizumab and IFN 
β-1a were the same within each subgroup level. Treatment-
by-subgroup interaction tests were used to determine 
whether the treatment effect of ocrelizumab versus IFN 
β-1a was the same between the two levels of subgroup. 
p values < 0.05 from the treatment-by-subgroup interac-
tion test indicate that the treatment effect of ocrelizumab 
versus IFN β-1a was not the same between the two levels 
of subgroup.
For ARR, both subgroup-level and treatment-by-subgroup 
interactions testing were performed using a negative bino-
mial or quasi-Poisson model with the number of relapses 
as the response variable and log-transformed exposure time 
as the offset variable in both models. Factors included in 
subgroup-level tests were treatment, study, region, and base-
line EDSS score (< 4.0 versus ≥ 4.0); additional factors in 
treatment-by-subgroup interaction testing were subgroup 
and treatment-by-subgroup interaction.
Disability progression, with 12- or 24-week confirmation, 
subgroup-level, and treatment-by-subgroup interactions test-
ing were performed using Cox proportional hazard models 
with time to onset of disability progression as the response 
variable and treatment (ocrelizumab versus IFN β-1a) as a 
factor, and study, region and baseline EDSS score (< 4.0 
versus ≥ 4.0) as adjustments in both models; additional fac-
tors in the treatment-by-subgroup interaction testing were 
subgroups and treatment-by-subgroup interaction.
For the MRI outcomes of T1 gadolinium-enhancing lesions 
and new/enlarging T2 lesions, subgroup-level and treatment-
by-subgroup interactions testing were performed using a 
negative binomial or quasi-Poisson model with the number of 
lesions as the response variable, the log-transformed number 
of MRI scans as the offset variable, and baseline lesion count, 
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treatment, study, region, and baseline EDSS score (< 4.0 ver-
sus ≥ 4.0) as factors in both models; additional factors in the 
treatment-by-subgroup interaction tests were subgroup and 
treatment-by-subgroup interaction. For change from baseline 
brain volume, subgroup and treatment-by-subgroup interaction 
testing used a mixed-effect model of repeated measures model 
(unstructured covariance matrix) with percentage change in 
brain volume as the dependent variable and baseline brain 
volume, treatment, study, region, baseline EDSS score (< 4.0 
versus ≥ 4.0), week, baseline brain volume-by-week, and treat-
ment-by-week as factors in both models; additional factors in 
the treatment-by-subgroup interaction tests were subgroup and 
treatment-by-week-by-subgroup.
Subgroup-level testing of NEDA or NEDA 24–96 (NEDA 
rebaselined at Week 24, which provides a representation of 
steady-state efficacy unconfounded by any initial disease 
activity carried over from baseline and recent pre-baseline 
disease state [4]) used the Cochran–Mantel–Haenszel test 
with treatment and NEDA status as the column/row factors 
and study, region, and baseline EDSS score (< 4.0 versus 
≥ 4.0) as stratification factors. Treatment-by-subgroup inter-
action used the Breslow–Day test with treatment/NEDA sta-
tus as the column/row factors and subgroup as the stratifica-
tion factor.
For subgroup-level analyses, key covariates (i.e., study, 
region, or baseline EDSS < 4.0 versus ≥ 4.0) were not 
included as a main effect if the key covariate was used as 
the subgroup. If the subgroup was EDSS < 2.5 versus ≥ 2.5, 
then baseline EDSS < 4.0 versus ≥ 4.0 was not included as 
a main effect.
Analyses of patients who were pre-treated and had active 
or highly active disease were conducted in a similar way to 
the subgroup-level analyses described above, with the excep-
tion that no treatment-by-subgroup testing was conducted.
Results
Patient disposition, demographic and disease characteris-
tics, and safety findings from the individual OPERA I and 
OPERA II studies were reported previously [1]. Baseline 
demographic and disease characteristics between treatment 
groups in the pooled ITT population were generally compa-
rable (Table 1), and characteristics within the mITT popu-
lation were generally comparable to those within the ITT 
population (Supplementary Table S1).
Subgroup analyses
Annualized relapse rate
The significant reduction in ARR observed in the overall 
pooled analysis of the ITT population with ocrelizumab, 
relative to IFN β-1a (47% [p < 0.001]), was maintained 
across the majority of subgroup-levels, including study, 
region, age, sex, baseline BMI, prior DMT use and prior 
relapse, baseline EDSS, normalized brain volume, and gad-
olinium-enhancing T1 lesions; a numerical trend favoring 
ocrelizumab was observed for the specific subgroup strata 
of patients aged ≥ 40 years (Fig. 1).
Significant treatment-by-subgroup interactions for ARR 
were observed between patients aged < 40 versus ≥ 40 years 
(p = 0.006) and patients with or without baseline T1 gadolin-
ium-enhancing lesions (p < 0.001). Treatment-by-subgroup 
interaction p values for all endpoints and subgroups are pre-
sented in Supplementary Table S2.
Confirmed disability progression
The significant reductions in disease progression with 
12-week confirmation (40% [p < 0.001]; Fig. 2) and 24-week 
confirmation (40% [p = 0.003]; Supplementary Fig. S1), 
relative to IFN β-1a, observed in the overall pooled anal-
ysis of the ITT population were maintained across most 
subgroup-levels.
For 12W-CDP, numerical trends favoring ocrelizumab 
were observed in the subgroup strata of patients: from the 
USA, who received prior DMT, with ≥ 2 prior relapses 
at baseline, with a baseline EDSS score < 2.5, or with a 
baseline BMI ≥ 25 kg/m2 (Fig. 2). The pattern of numeri-
cal trends favoring ocrelizumab for 24W-CDP was the 
same as for 12W-CDP with the addition of trends for males 
and for patients with a baseline normalized brain volume 
< 1500 cm3 (Supplementary Fig. S1).
Significant treatment-by-subgroup interactions were 
observed between patients with a baseline BMI < 25 kg/
m2 versus ≥ 25 kg/m2 for both 12W-CDP (p = 0.026) and 
24W-CDP (p = 0.016; Fig. 2).
MRI outcomes
The substantial reductions in both the average number of 
gadolinium-enhancing T1 lesions (94% [p < 0.001]; Fig. 3) 
and the average number of new or newly enlarged hyper-
intense T2 lesions per scan (80% [p < 0.001]; Fig. 4), of 
ocrelizumab relative to IFN β-1a, observed in the overall 
pooled analysis of the ITT population were maintained 
across all subgroup-levels (p < 0.001 for both endpoints and 
all comparisons).
For T1 gadolinium-enhancing lesions, treatment-by-sub-
group interactions were observed between patients aged < 40 
versus ≥ 40 years (p = 0.030) and patients with or without 
baseline T1 gadolinium-enhancing lesions (p = 0.001). With 
respect to new or newly enlarged hyperintense T2 lesions, 
treatment-by-subgroup interactions were observed between 
patients with a baseline EDSS score < 4.0 versus ≥ 4.0 
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(p = 0.007) and a baseline BMI < 25 kg/m2 versus ≥ 25 kg/m2 
(p = 0.043).
The benefit in change from baseline brain volume 
observed in the overall pooled analysis of the ITT pop-
ulation with ocrelizumab, relative to IFN β-1a (least 
square mean difference, 0.31% [p < 0.001]; Fig. 5), was 
maintained across the majority of subgroup-levels; a 
numerical trend favoring ocrelizumab was observed in 
patients from the USA. A treatment-by-subgroup inter-
action was observed between patients with a normal-
ized baseline brain volume < 1500 cm3 and ≥ 1500 cm3 
(p = 0.002).
Table 1  Baseline demographic 
and disease characteristics 
of the pooled OPERA I and 
OPERA II intent-to-treat 
population
DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, IFN interferon, MRI magnetic 
resonance imaging, MS multiple sclerosis, OCR ocrelizumab, RMS relapsing multiple sclerosis, SD stand-
ard deviation
a Data include patients who were untreated with any DMT in the 2 years before screening
b IFN β-1a n = 826, OCR n = 825
c IFN β-1a n = 828
d IFN β-1a n = 827, OCR n = 826
e IFN β-1a n = 822, OCR n = 818
f IFN β-1a n = 824, OCR n = 822
g IFN β-1a n = 818, OCR n = 820
Characteristic IFN β-1a 44 µg 
(N = 829)
Ocrelizumab 
600 mg 
(N = 827)
Age
 Years, mean (SD) 37.2 (9.2) 37.1 (9.2)
 < 40 years, n (%) 484 (58.4) 496 (60.0)
 ≥ 40 years, n (%) 345 (41.6) 331 (40.0)
Female, n (%) 552 (66.6) 541 (65.4)
Body mass index
 kg/m2, mean (SD) 26.4 (6.2) 26.2 (5.8)
 < 25 kg/m2, n (%) 413 (50.2) 406 (49.6)
 ≥ 25 kg/m2, n (%) 409 (49.8) 412 (50.4)
Time since MS symptom onset, years, mean (SD) 6.5 (6.1) 6.7 (6.2)
Time since RMS diagnosis, years, mean (SD) 3.9 (4.9) 4.0 (4.9)
No DMT in the 2 years before study inclusion, n (%) 606 (73.4)a,b 605 (73.3)a,b
EDSS score
 Mean (SD) 2.8 (1.3)c 2.8 (1.3)
 < 2.5, n (%) 329 (39.7)c 310 (37.5)
 ≥ 2.5, n (%) 499 (60.3)c 517 (62.5)
 < 4.0, n (%) 627 (75.7)c 629 (76.1)
 ≥ 4.0, n (%) 201 (24.3)c 198 (23.9)
Number of relapses, mean (SD)
 In the last year, mean (SD) 1.33 (0.69)d 1.32 (0.67)d
 In the last 2 years, mean (SD) 1.76 (0.92)d 1.79 (0.91)d
 ≤ 1 relapse, n (%) 584 (70.6)d 585 (70.8)d
 ≥ 2 relapses, n (%) 243 (29.4)d 241 (29.2)d
MRI
 Patients with no T1 gadolinium-enhancing lesions, n (%) 495 (60.2)e 485 (59.3)e
 Patients with ≥ 1 T1 gadolinium-enhancing lesion, n (%) 327 (39.8)e 333 (40.7)e
 Number of T2 lesions, mean (SD) 51 (38)f 50 (39)f
 T2 lesion volume,  cm3, mean (SD) 10.18 (11.8)f 10.79 (14.1)f
 Normalized brain volume,  cm3, mean (SD) 1500 (89)g 1502 (88)g
 Normalized brain volume < 1500 cm3, n (%) 398 (48.7)g 402 (49.0)g
 Normalized brain volume ≥ 1500 cm3, n (%) 420 (51.3)g 418 (51.0)g
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No evidence of disease activity
The increase in the proportion of patients with NEDA in 
the overall pooled mITT population with ocrelizumab (75% 
[p < 0.001]), relative to IFN β-1a, was maintained across 
most subgroup-levels (Fig. 6); a numerical trend favor-
ing ocrelizumab was observed in patients with a baseline 
EDSS score ≥ 4.0. A treatment-by-subgroup interaction was 
observed between patients with a baseline EDSS score < 4.0 
and ≥ 4.0 (p = 0.022).
Similarly, when NEDA was rebaselined to Week 
24, the improvement in the proportion of patients 
with NEDA 24–96 seen in the overall pooled mITT 
population with ocrelizumab (72% [p < 0.001]), relative 
to IFN β-1a, was maintained across all subgroup-levels 
 (Supplementary Fig. S2). Treatment-by-subgroup inter-
actions were observed between patients with a baseline 
EDSS score < 4.0 and ≥ 4.0 (p = 0.008), patients < 40 and 
≥ 40 years old (p < 0.001), and those with or without T1 
gadolinium-enhancing lesions at baseline (p < 0.001).
Efficacy in pre‑treated patients with active or highly 
active disease
A total of 301 patients were defined as pre-treated with 
active disease (ocrelizumab, n = 153; IFN β-1a, n = 148) 
IFN β-1a (N ( RCO)928= N=827)
Group,
n
 Relapses,
n
Patient
years
Adjusted
ARR
Group,
n
Relapses,
n
Patient
years
Adjusted
ARR
 
All patients 829 334 1339.16 0.29 827 194 1415.72 0.16
Study
OPERA I 411 166 678.12 0.29 410 96 706.26 0.16
OPERA II 418 168 661.04 0.29 417 98 709.45 0.16
Region
ROW 610 254 1013.69 0.29 610 143 1058.03 0.15
USA 219 80 325.47 0.29 217 51 357.69 0.17
Age, yearsa
<40 484 212 779.40 0.36 496 103 846.48 0.15
≥40 345 122 559.76 0.23 331 91 569.23 0.17
Sex
Female 552 233 887.84 0.30 541 130 920.62 0.16
Male 277 101 451.33 0.25 286 64 495.09 0.14
Baseline body mass index, kg/m2
<25 413 171 668.23 0.30 406 98 696.53 0.16
≥25 409 160 658.05 0.28 412 94 703.99 0.15
Baseline normalized brain volume, cm3 
<1500 398 168 645.88 0.28 402 103 688.08 0.16
≥1500 420 165 678.61 0.33 418 91 714.72 0.16
Prior disease-modifying therapy use in the 2 years before study inclusion
No 605 226 995.71 0.28 604 137 1034.43 0.16
Yes 224 108 343.46 0.32 223 57 381.29 0.15
Prior relapseb
≤1 584 203 942.02 0.24 585 122 1000.77 0.14
≥2 243 130 394.84 0.38 241 72 413.87 0.20
Baseline Expanded Disability Status Scale scoreb
<4 627 226 1023.33 0.22 629 118 1081.62 0.11
≥4 201 108 315.78 0.35 198 76 334.10 0.23
<2.5 329 113 540.27 0.21 310 52 530.56 0.10
≥2.5 499 221 798.85 0.29 517 142 885.16 0.16
Baseline T1 gadolinium-enhancing lesions, na
0 495 164 811.56 0.25 485 124 828.95 0.18
≥1 327 167 519.59 0.35 333 70 570.93 0.13
0.54 (95% CI: 0.44–0.66; p<0.001)
0.54 (95% CI: 0.40–0.72; p<0.001)
0.53 (95% CI: 0.40–0.71; p<0.001)
0.52 (95% CI: 0.41–0.67; p<0.001)
0.58 (95% CI: 0.39–0.85; p=0.005)
0.41 (95% CI: 0.31–0.55; p<0.001)
0.76 (95% CI: 0.56–1.03; p=0.073)
0.53 (95% CI: 0.41–0.68; p<0.001)
0.56 (95% CI: 0.40–0.80; p=0.001)
0.52 (95% CI: 0.39–0.70; p<0.001)
0.55 (95% CI: 0.41–0.73; p<0.001)
0.58 (95% CI: 0.43–0.76; p<0.001)
0.49 (95% CI: 0.36–0.67; p<0.001)
0.57 (95% CI: 0.45–0.72; p<0.001)
0.46 (95% CI: 0.31–0.69; p=0.001)
0.57 (95% CI: 0.45–0.71; p<0.001)
0.53 (95% CI: 0.40–0.71; p<0.001)
0.49 (95% CI: 0.40–0.62; p<0.001)
0.67 (95% CI: 0.50–0.89; p=0.006)
0.46 (95% CI: 0.31–0.69; p<0.001)
0.57 (95% CI: 0.45–0.73; p<0.001)
0.74 (95% CI: 0.56–0.96; p=0.025)
0.36 (95% CI: 0.26–0.50; p<0.001)
0.00 0.50 1.00 1.50 2.00
Rate ratio
Favors OCR Favors IFN β-1a
Fig. 1  Annualized relapse rate by subgroup in the pooled OPERA I 
and OPERA II intent-to-treat population. Subgroup-level and treat-
ment-by-subgroup interactions were assessed by the negative bino-
mial method, or quasi-Poisson model if appropriate (where indicated). 
ARR annualized relapse rate, CI confidence interval, IFN interferon, 
OCR ocrelizumab, ROW rest of world. aA significant treatment-by-
subgroup interaction was observed for age (< 40 versus ≥ 40 years; 
p = 0.006) and for baseline T1 gadolinium-enhancing lesion status (0 
versus ≥ 1; p < 0.001); p values < 0.05 from the treatment-by-subgroup 
interaction test indicate that the treatment effect of OCR versus IFN 
is not the same at each subgroup-level. bEstimated by quasi-Poisson 
model
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and 283 patients were defined as pre-treated with highly 
active disease (ocrelizumab, n = 143; IFN β-1a, n = 140). 
Consistent with the reduction in ARR in the overall ITT 
pooled population (47%; p < 0.001), ocrelizumab, relative 
to IFN β-1a, reduced the ARR in patients who were pre-
treated with active disease by 65% (p < 0.001) and pre-
treated with highly active disease by 68% (p < 0.001).
Similar benefits in patients who were pre-treated with 
active disease or pre-treated with highly active disease were 
observed for 12W-CDP (54% relative reduction [p = 0.032] 
or a 53% relative reduction [p = 0.035], respectively) com-
pared with a 40% reduction (p < 0.001) in the overall ITT 
pooled population; 24W-CDP (51% relative reduction 
[p = 0.075] or a 50% relative reduction [p = 0.082], respec-
tively) compared with a 40% reduction (p = 0.003) in the 
overall ITT pooled population; T1 gadolinium-enhancing 
lesions (98% relative reduction [p < 0.001 in both sub-
groups]) compared with a 94% reduction (p < 0.001) in 
the overall ITT pooled population; and new or enlarging 
T2 lesions (80% relative reduction [p < 0.001 in both sub-
groups]) compared with an 80% reduction (p < 0.001) in 
the overall ITT pooled population.
For patients who were pre-treated with either active 
or highly active disease, the statistically significant treat-
ment benefits of ocrelizumab relative to IFN β-1a were 
IFN β-1a (N=829) OCR (N=827)
Group,
n
 Events,
n
 Group,
n
 Events,
n
 
All patients 829 113 827 75
Study
OPERA I 411 50 410 31
OPERA II 418 63 417 44
Region
ROW 610 79 610 45
USA 219 34 217 30
Age, years
<40 484 53 496 34
≥40 345 60 331 41
Sex
Female 552 70 541 48
Male 277 43 286 27
Baseline body mass index, kg/m2 a
<25 413 54 406 23
≥25 409 59 412 51
Baseline normalized brain volume, cm3
<1500 398 64 402 43
≥1500 420 47 418 32
Prior disease-modifying therapy use in the 2 years
before study inclusion
No 605 82 604 53
Yes 224 31 223 22
Prior relapse
≤1 584 82 585 52
≥2 243 31 241 23
Baseline Expanded Disability Status Scale score
<4 627 87 629 64
≥4 201 26 198 11
<2.5 329 44 310 37
≥2.5 499 69 517 38
Baseline T1 gadolinium-enhancing lesions, n
0 495 65 485 43
≥1 327 47 333 32
0.60 (95% CI: 0.45–0.81; p<0.001)
0.57 (95% CI: 0.37–0.90; p=0.015)
0.63 (95% CI: 0.42–0.92; p=0.018) 
0.53 (95% CI: 0.36–0.76; p<0.001)
0.77 (95% CI: 0.47–1.26; p=0.3)
0.59 (95% CI: 0.39–0.92; p=0.019)
0.61 (95% CI: 0.41–0.92; p=0.018)
0.64 (95% CI: 0.44–0.93; p=0.019)
0.56 (95% CI: 0.34–0.91; p=0.019)
0.39 (95% CI: 0.24–0.64; p<0.001)
0.81 (95% CI: 0.55–1.18; p=0.3)
0.61 (95% CI: 0.41–0.90; p=0.013)
0.63 (95% CI: 0.40–0.99; p=0.046)
0.60 (95% CI: 0.42–0.85; p=0.004)
0.61 (95% CI: 0.35–1.06; p=0.080)
0.58 (95% CI: 0.41–0.82; p=0.002)
0.67 (95% CI: 0.39–1.16; p=0.2)
0.66 (95% CI: 0.48–0.92; p=0.014)
0.39 (95% CI: 0.19–0.80; p=0.010)
0.82 (95% CI: 0.53–1.27; p=0.4)
0.48 (95% CI: 0.33–0.72; p<0.001)
0.60 (95% CI: 0.40–0.88; p=0.010)
0.60 (95% CI: 0.38–0.95; p=0.029)
0.00 0.50 1.00 1.50 2.00
Hazard ratio
Favors IFN β-1aFavors OCR
Fig. 2  Disease progression confirmed at Week 12 by subgroup in 
the pooled OPERA I and OPERA II intent-to-treat population. Sub-
group-level and treatment-by-subgroup interactions were assessed 
by the Cox proportional hazards method. CI confidence interval, 
IFN interferon, OCR ocrelizumab, ROW rest of world. aA significant 
treatment-by-subgroup interaction was observed for BMI (< 25 kg/m2 
versus ≥ 25 kg/m2; p = 0.026); p values < 0.05 from the treatment-by-
subgroup interaction test indicate that the treatment effect of OCR 
versus IFN is not the same at each subgroup-level
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demonstrated for all endpoints except for 24W-CDP, which 
comprised a relatively smaller number of patients.
Discussion
In the OPERA I and OPERA II studies, ocrelizumab, rela-
tive to IFN β-1a, was associated with significantly better out-
comes in terms of ARR, disability progression, suppression 
of new inflammatory lesions in the brain (T1 gadolinium-
enhancing lesions), and new or newly enlarged plaque forma-
tion (new/enlarging T2 lesions) [1]. The subgroup analyses 
presented here demonstrate that the significant treatment 
benefits of ocrelizumab, relative to IFN β-1a, are maintained 
across most baseline-, clinically, and radiologically defined 
subgroups, although the magnitude of the treatment benefit of 
ocrelizumab over IFN β-1a may be greater in one of the two 
levels of subgroup. Treatment-by-subgroup interactions were 
observed for some endpoints over particular subgroups; how-
ever, all showed a benefit (significant or numerical) of ocre-
lizumab over IFN β-1a at each of the two levels of subgroup.
OPERA I and OPERA II were not powered to detect 
statistically significant effects for all subgroup analyses, 
including those predefined and with pre-planned pool-
ing (12W-CDP or 24W-CDP), or to test for heterogene-
ity between subgroups. Additionally, post hoc analyses of 
IFN β-1a (N=829) OCR (N=827)
Group,
n
 Lesions,
n
 MRIs,
n 
Group,
n 
Lesions,
n
 MRIs,
n
 
All patients 829 802 2081 827 42 2235
Study
OPERA I 411 337 1064 410 21 1118
OPERA II 418 465 1017 417 21 1117
Region
ROW 610 474 1590 610 27 1686
USA 219 328 491 217 15 549
Age, yearsa,b
<40 484 594 1208 496 24 1331
≥40 345 208 873 331 18 904
Sex
Female 552 558 1376 541 32 1445
Male 277 244 705 286 10 790
Baseline body mass index, kg/m2
<25 413 444 1044 406 23 1105
≥25 409 358 1016 412 19 1106
Baseline normalized brain volume, cm3  
<1500 398 388 1001 402 18 1090
≥1500 420 404 1059 418 24 1126
Prior disease-modifying therapy use in the 2 years before study inclusionb
No 605 544 1550 604 31 1632
Yes 224 258 531 223 11 603
Prior relapseb
≤1 584 508 1463 585 19 1575
≥2 243 293 615 241 23 659
Baseline Expanded Disability Status Scale scoreb
<4 627 673 1597 629 32 1707
≥4 201 129 484 198 10 528
<2.5 329 315 843 310 20 841
≥2.5 499 487 1238 517 22 1394
Baseline T1 gadolinium-enhancing lesionsa
0 495 173 1274 485 20 1310
≥1 327 626 801 333 22 905
0.06 (95% CI: 0.04–0.08; p<0.001)
0.06 (95% CI: 0.03–0.10; p<0.001)
0.05 (95% CI: 0.03–0.09; p<0.001) 
0.06 (95% CI: 0.03–0.09; p<0.001)
0.05 (95% CI: 0.02–0.10; p<0.001)
0.04 (95% CI: 0.03–0.06; p<0.001)
0.08 (95% CI: 0.05–0.13; p<0.001)
0.07 (95% CI: 0.04–0.11; p<0.001)
0.04 (95% CI: 0.02–0.07; p<0.001)
0.05 (95% CI: 0.03–0.09; p<0.001)
0.05 (95% CI: 0.03–0.08; p<0.001)
0.04 (95% CI: 0.02–0.07; p<0.001)
0.06 (95% CI: 0.03–0.10; p<0.001)
0.05 (95% CI: 0.04–0.08; p<0.001)
0.03 (95% CI: 0.02–0.06; p<0.001)
0.04 (95% CI: 0.02–0.06; p<0.001)
0.06 (95% CI: 0.04–0.10; p<0.001)
0.04 (95% CI: 0.03–0.06; p<0.001)
0.08 (95% CI: 0.04–0.14; p<0.001)
0.07 (95% CI: 0.03–0.12; p<0.001)
0.05 (95% CI: 0.03–0.08; p<0.001)
0.11 (95% CI: 0.06–0.21; p<0.001)
0.03 (95% CI: 0.02–0.05; p<0.001)
0.00 0.50 1.00 1.50 2.00
Rate ratio
Favors IFN β-1aFavors OCR
Fig. 3  T1 gadolinium-enhancing lesions by subgroup in the pooled 
OPERA I and OPERA II intent-to-treat population. Subgroup-level 
and treatment-by-subgroup interactions were assessed by the nega-
tive binomial method, or quasi-Poisson model if appropriate (where 
indicated). CI confidence interval, IFN interferon, MRI magnetic res-
onance imaging, OCR ocrelizumab, ROW rest of world. aA significant 
treatment-by-subgroup interaction was observed for age (< 40 versus 
≥ 40 years; p = 0.030) and for baseline T1 gadolinium-enhancing 
lesion status (0 versus ≥ 1; p = 0.001); p values < 0.05 from the treat-
ment-by-subgroup interaction test indicate that the treatment effect of 
OCR versus IFN is not the same at each subgroup-level. bEstimated 
by quasi-Poisson model
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subgroups can be difficult to interpret. Within this analysis 
most outcomes and subgroups were predefined; only NEDA 
24–96 and brain volume change from baseline for outcomes, 
and the subgroups baseline EDSS score < 2.5 versus ≥ 2.5, 
prior DMT use yes versus no, those with ≤ 1 or ≥ 2 prior 
relapses, and those with a baseline normalized brain volume 
of < 1500 cm3 or ≥ 1500 cm3, were post hoc considerations.
Consequently, given the relatively smaller numbers of 
subjects in some of the subgroups, findings in these sub-
groups should be interpreted with caution. Further studies 
with an expanded data set with improved assessment tech-
niques would be required to address these points.
For ARR, gadolinium-enhancing T1 lesions, and NEDA 
rebaselined at Week 24, significant subgroup interactions sug-
gested that patients who were younger and those with indica-
tors of active inflammatory disease appeared to gain a greater 
treatment benefit with ocrelizumab, relative to IFN β-1a, than 
patients who were older and those without markers of active 
inflammatory disease. These findings are consistent with treat-
ment benefit of other DMTs, which has previously been sug-
gested to be higher in younger than in older patients on the 
basis of higher disease activity in younger populations with 
MS [5]. Subgroup analyses performed for other DMTs using 
either placebo or an active comparator, e.g., fingolimod [6, 7], 
cladribine [8], teriflunomide [9], dimethyl fumarate [10–12], 
IFN β-1a (N=829) OCR (N=827)
Group,
n 
Lesions,
n 
MRIs,
n 
Group,
n
 Lesions,
n 
MRIs,
n 
All patients 829 4019 2091 827 810 2246
Study
OPERA I 411 1916 1066 410 430 1123
OPERA II 418 2103 1025 417 380 1123
Region
ROW 610 2821 1595 610 595 1690
USA 219 1198 496 217 215 556
Age, years
<40 484 3064 1216 496 615 1340
≥40 345 955 875 331 195 906
Sex
Female 552 2281 1384 541 484 1457
Male 277 1738 707 286 326 789
Baseline body mass index, kg/m2 a
<25 413 2181 1047 406 514 1107
≥25 409 1825 1023 412 290 1115
Baseline normalized brain volume, cm3 
<1500 398 1855 1004 402 317 1095
≥1500 420 2125 1066 418 492 1133
Prior disease-modifying therapy use in the 2 years before study inclusion
No 605 2709 1557 604 567 1641
Yes 224 1310 534 223 243 605
Prior relapse
≤1 584 2636 1469 585 532 1584
≥2 243 1381 619 241 278 661
Baseline Expanded Disability Status Scale scorea
<4 627 3225 1604 629 546 1719
≥4 201 794 487 198 264 527
<2.5 329 1738 849 310 285 844
≥2.5 499 2281 1242 517 525 1402
Baseline T1 gadolinium-enhancing lesions, n
0 495 945 1277 485 195 1313
≥1 327 3070 804 333 612 910
0.20 (95% CI: 0.16–0.24; p<0.001)
0.23 (95% CI: 0.17–0.30; p<0.001)
0.17 (95% CI: 0.13–0.23; p<0.001)
0.20 (95% CI: 0.16–0.26; p<0.001)
0.19 (95% CI: 0.13–0.27; p<0.001)
0.18 (95% CI: 0.14–0.23; p<0.001)
0.23 (95% CI: 0.16–0.33; p<0.001)
0.20 (95% CI: 0.16–0.26; p<0.001)
0.18 (95% CI: 0.13–0.25; p<0.001)
0.22 (95% CI: 0.17–0.30; p<0.001)
0.15 (95% CI: 0.12–0.20; p<0.001)
0.18 (95% CI: 0.14–0.24; p<0.001)
0.20 (95% CI: 0.15–0.25; p<0.001)
0.21 (95% CI: 0.17–0.27; p<0.001)
0.16 (95% CI: 0.11–0.23; p<0.001)
0.19 (95% CI: 0.15–0.25; p<0.001)
0.20 (95% CI: 0.14–0.28; p<0.001)
0.17 (95% CI: 0.14–0.21; p<0.001)
0.32 (95% CI: 0.21–0.50; p<0.001)
0.17 (95% CI: 0.12–0.22; p<0.001)
0.22 (95% CI: 0.17–0.28; p<0.001)
0.21 (95% CI: 0.16–0.29; p<0.001)
0.17 (95% CI: 0.14–0.22; p<0.001)
0.00 0.50 1.00 1.50 2.00
Rate ratio
Favors IFN β-1aFavors OCR
Fig. 4  New/enlarging T2 lesions by subgroup in the pooled OPERA I 
and OPERA II intent-to-treat population. Subgroup-level and treat-
ment-by-subgroup interactions were assessed by the negative bino-
mial method, or quasi-Poisson model if appropriate (where indicated). 
CI confidence interval, EDSS Expanded Disability Status Scale, 
IFN interferon, MRI magnetic resonance imaging, OCR ocrelizumab, 
ROW rest of world. aA significant treatment-by-subgroup interaction 
was observed for baseline BMI (< 25 versus ≥ 25 kg/m2; p = 0.043) and 
baseline EDSS score (< 4.0 versus ≥ 4.0; p = 0.007); p values < 0.05 
from the treatment-by-subgroup interaction test indicate that the treat-
ment effect of OCR versus IFN is not the same at each subgroup-level
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alemtuzumab [13], and natalizumab [14, 15], also found that 
efficacy was highest in younger patients with more active 
disease.
Consistent effects across endpoints were seen for other 
subgroups of interest. There were no significant sex-
based subgroup interactions and the same positive trends 
of treatment benefit with ocrelizumab were reported in 
female and male patients. The treatment benefit of ocreli-
zumab, relative to IFN β-1a, was comparable across end-
points in patients with active or highly active disease who 
were pre-treated with DMT, while prior treatment per se 
did not impact the magnitude of the beneficial effect of 
ocrelizumab. Across other endpoints, the magnitude of 
ocrelizumab’s treatment benefit on brain atrophy was 
greater in patients with lower baseline brain volume, 
which may be related to differential rates of atrophy in 
the patient subgroups defined by brain volume thresh-
olds. For NEDA (Weeks 0–96) and new or enlarging T2 
lesion endpoints, the treatment benefit of ocrelizumab was 
greater in patients with lower measures of disability at 
baseline. For both 12W-CDP and 24W-CDP, significant 
treatment-by-subgroup interactions for BMI indicate that 
the magnitude of ocrelizumab treatment benefit is greater 
in lighter patients versus heavier, consistent with lower 
ocrelizumab exposure in heavier patients (BMI > 25 kg/m2 
versus < 25 kg/m2). Analyses have shown that patients 
IFN β-1a (N=829) OCR (N=827)
Group,
n
 Change frombaseline,
LS mean (%)
Group,
n
Change from
baseline,
LS mean (%)
 
  
 
 
All patients 707 –1.29 827 –0.99
Study
OPERA I 353 –1.23 410 –0.94
OPERA II 354 –1.35 417 –1.03
Region
ROW 529 –1.34 610 –0.98
USA 178 –1.17 217 –1.02
Age, years
<40 413 –1.31 496 –1.09
≥40 294 –1.29 331 –0.85
Sex
Female 471 –1.34 541 –0.97
Male 236 –1.21 286 –1.01
Baseline body mass index, kg/m2
<25 360 –1.31 406 –1.01
≥25 340 –1.27 412 –0.95
Baseline normalized brain volume, cm3 a  
<1500 338 –1.54 402 –1.06
≥1500 369 –1.08 418 –0.94
Prior disease-modifying therapy use in the 2 years
before study inclusion 
No 521 –1.33 604 –1.02
Yes 186 –1.19 223 –0.90
Prior relapse
≤1 494 –1.27 585 –0.97
≥2 212 –1.37 241 –1.04
Baseline Expanded Disability Status Scale score
<4 539 –1.24 629 –0.94
≥4 168 –1.43 198 –1.09
<2.5 287 –1.11 310 –0.92
≥2.5 420 –1.39 517 –1.01
Baseline T1 gadolinium-enhancing lesions, n
0 427 –1.06 485 –0.74
≥1 278 –1.64 333 –1.34
0.31 (95% CI: 0.20–0.42; p<0.001)
0.29 (95% CI: 0.15–0.43; p<0.001)
0.32 (95% CI: 0.16–0.49; p<0.001)
0.36 (95% CI: 0.23–0.49; p<0.001)
0.15 (95% CI: –0.06–0.37; p=0.2)
0.22 (95% CI: 0.08–0.37; p=0.003)
0.44 (95% CI: 0.28–0.60; p<0.001)
0.37 (95% CI: 0.23–0.50; p<0.001)
0.20 (95% CI: 0.01–0.39; p=0.044)
0.30 (95% CI: 0.14–0.47; p<0.001)
0.32 (95% CI: 0.18–0.47; p<0.001)
0.48 (95% CI: 0.31–0.65; p<0.001)
0.14 (95% CI: 0.01–0.28; p=0.042)
0.31 (95% CI: 0.18–0.43; p<0.001)
0.29 (95% CI: 0.08–0.50; p=0.007)
0.30 (95% CI: 0.17–0.43; p<0.001)
0.33 (95% CI: 0.13–0.53; p=0.002)
0.30 (95% CI: 0.18–0.42; p<0.001)
0.34 (95% CI: 0.07–0.61; p=0.013)
0.19 (95% CI: 0.04–0.34; p=0.014)
0.38 (95% CI: 0.23–0.53; p<0.001)
0.32 (95% CI: 0.21–0.44; p<0.001)
0.31 (95% CI: 0.12–0.50; p=0.002)
0.16.04.02.0–
Least square mean difference, %
Favors OCRFavors IFN β-1a
8.02.00.0
Fig. 5  Change from baseline brain volume (%) by subgroup in the 
pooled OPERA I and OPERA II intent-to-treat population. Subgroup-
level and treatment-by-subgroup interactions were assessed by the 
mixed-effect model of repeated measures model. CI confidence inter-
val, IFN interferon, LS least square, OCR ocrelizumab, ROW rest of 
world. aA significant treatment-by-subgroup interaction was observed 
for normalized baseline brain volume (< 1500 cm3 and ≥ 1500 cm3; 
p = 0.002); p values < 0.05 from the treatment-by-subgroup interac-
tion test indicate that the treatment effect of OCR versus IFN is not 
the same at each subgroup-level
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with a higher ocrelizumab exposure had a greater benefit 
on 12W-CDP and 24W-CDP. Therefore, it might be pos-
sible that in the BMI subgroups the ocrelizumab expo-
sure had an influence on confirmed disability progression 
results. However, a contradictory significant treatment-by-
subgroup interaction between BMI strata was observed 
(p = 0.043) for the endpoint of new or enlarging T2 lesion 
endpoints, indicating a higher magnitude of ocrelizumab 
treatment benefit in heavier versus lighter patients; how-
ever, this finding requires further study before clinical 
meaningfulness can be confirmed. Subgroup analyses 
of other studies with MS DMTs have demonstrated an 
interaction between age and disability progression, with 
lower levels of progression in younger patients; this was 
not observed in the current study.
In conclusion, the treatment benefit of ocrelizumab ver-
sus IFN β-1a, measured by clinical and MRI outcomes, 
was maintained across almost all the subgroups and strata 
of interest, and the pattern of treatment benefit across 
all subgroups was consistent with that from the pooled 
OPERA studies. The results show that RMS patients with 
a wide range of demographic and clinical characteristics 
benefit more from treatment with ocrelizumab than from 
IFN β-1a.
IFN β-1a (N=759) OCR (N=761)
Group,
n
 NEDA,
n (%) 
Group,
n
NEDA,
n (%) 
All patients 759 206 (27.1) 761 363 (47.7)
Study
OPERA I 384 112 (29.2) 382 183 (47.9)
OPERA II 375 94 (25.1) 379 180 (47.5)
Region
ROW 567 163 (28.7) 570 291 (51.1)
USA 192 43 (22.4) 191 72 (37.7)
Age, years
<40 447 101 (22.6) 454 201 (44.3)
≥40 312 105 (33.7) 307 162 (52.8)
Sex
Female 507 150 (29.6) 493 245 (49.7)
Male 252 56 (22.2) 268 118 (44.0)
Baseline body mass index, kg/m2
<25 382 106 (27.7) 374 176 (47.1)
≥25 370 98 (26.5) 379 183 (48.3)
Baseline normalized brain volume, cm3
<1500 364 92 (25.3) 371 172 (46.4)
≥1500 385 112 (29.1) 383 185 (48.3)
Prior disease-modifying therapy use in the 2 years before
study inclusion 
No 558 158 (28.3) 553 274 (49.5)
Yes 201 48 (23.9) 208 89 (42.8)
Prior relapse
≤1 531 155 (29.2) 537 264 (49.2)
≥2 226 51 (22.6) 224 99 (44.2)
Baseline Expanded Disability Status Scale scorea
<4 579 153 (26.4) 579 291 (50.3)
≥4 180 53 (29.4) 182 72 (39.6)
<2.5 306 84 (27.5) 283 143 (50.5)
≥2.5 453 122 (26.9) 478 220 (46.0)
Baseline T1 gadolinium-enhancing lesions, n
0 449 174 (38.8) 441 263 (59.6)
≥1 303 31 (10.2) 312 94 (30.1)
1.75 (95% CI: 1.53–2.01; p<0.001)
1.64 (95% CI: 1.36–1.98; p<0.001)
1.89 (95% CI: 1.54–2.32; p<0.001)
1.78 (95% CI: 1.53–2.07; p<0.001)
1.66 (95% CI: 1.20–2.30; p=0.002)
1.99 (95% CI: 1.63–2.42; p<0.001)
1.55 (95% CI: 1.29–1.87; p<0.001)
1.66 (95% CI: 1.41–1.95; p<0.001)
2.05 (95% CI: 1.57–2.67; p<0.001)
1.70 (95% CI: 1.41–2.06; p<0.001)
1.82 (95% CI: 1.49–2.23; p<0.001)
1.84 (95% CI: 1.49–2.26; p<0.001)
1.67 (95% CI: 1.39–2.01; p<0.001)
1.75 (95% CI: 1.50–2.05; p<0.001)
1.79 (95% CI: 1.34–2.41; p<0.001)
1.68 (95% CI: 1.43–1.96; p<0.001)
2.00 (95% CI: 1.51–2.65; p<0.001)
1.91 (95% CI: 1.63–2.24; p<0.001)
1.31 (95% CI: 0.98–1.75; p=0.064)
1.85 (95% CI: 1.49–2.29; p<0.001)
1.70 (95% CI: 1.42–2.04; p<0.001)
1.55 (95% CI: 1.35–1.78; p<0.001)
2.85 (95% CI: 1.96–4.13; p<0.001)
Favors IFN β-1a
Rate ratio
5.45.20.25.0 0.45.35.10.1 3.0
Favors OCR
Fig. 6  Subgroup analyses of the proportion of patients with NEDA 
in the pooled OPERA I and OPERA II mITT population. Subgroup-
level testing used the Cochran–Mantel–Haenszel test and treatment-
by-subgroup interactions were assessed by the Breslow–Day test. 
CI confidence interval, EDSS Expanded Disability Status Scale, 
IFN interferon, mITT modified intent-to-treat, NEDA no evidence of 
disease activity, OCR ocrelizumab, ROW rest of world. aA significant 
treatment-by-subgroup interaction was observed for baseline EDSS 
score (< 4.0 versus ≥ 4.0; p = 0.022); p values < 0.05 from the treat-
ment-by-subgroup interaction test indicate that the treatment effect of 
OCR versus IFN is not the same at each subgroup-level
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